Laboratory of Biochemistry – Clinical Proteomic
|
The clinico-biological research focus of the team is in the field of neurodegenerative disorders and in particular in Alzheimer's disease (AD) that affects more than 800,000 people in France and represents a major public health problem. The team is at the forefront of biological diagnosis of this pathology by demonstrating the interest of biomarkers of cerebrospinal fluid (CSF) in routine and by proposing new recommendations for their use.
This activity is supported by the establishment of a BioBank with more than 1500 patients and the research programs of novel biomarkers (including a patent CHRU No. EP13305614.3 filed on 05/15/13). The LBPC is also a NFS 96-900 certified component of the Biological Resource Centre (CRB) of the CHRU de Montpellier. The team has a strong expertise in clinical Proteomics internationally recognized and supported with access to two analyzers of last generation for quantitative, differential (MRM and HRMS) mass spectrometry analyses. Thanks to access to clinical samples this expertise has enabled the team to propose innovative approaches in the field of clinical biology that are the basis of many publications and coordination or participation in clinical research programs as follows:
Figure 3
Figure 4
Bibliography
- Lehmann et al. (2015) Clin Chem Lab Med doi: 10.1515/cclm-2014-1232. [IF=3.01] [SIGAPS=18] - Dumurgier J… & Lehmann S (2015). Alzheimers Res Ther. In press [IF=3,5] [SIGAPS=24] - Lehmann et al (2014) Alzheimers Dement. doi: 10.1016/j.jalz.2014.09.003 [IF= 17.47] [SIGAPS=32] - Lehmann et al. (2014) PLoS ONE 9, no. 2: e88797 [IF=4,35] [SIGAPS=18] - Lehmann et al (2014) Alzheimers Res Ther. 2014 Jun 26;6(3):38 [IF=3,5] [SIGAPS=24] - Dauvilliers, Lehmann et al. (2014) Front Aging Neurosci. doi: 10.3389 [IF=2,84] [SIGAPS=18] - Gabelle et al (2014) Alzheimers Dement. doi: 10.1016/j.jalz.2014.04.515 [IF= 17.47] [SIGAPS=32] - Lehmann et al (2013) Alzheimers Dement. Epub 2013/11/26 [IF= 14.48] [SIGAPS=32] - Dumurgier et al (2013) Neurobiol Dis. 2013 Feb 13. doi:pii: S0969-9961. [IF=5.62] [SIGAPS=24] - Lehmann et al. (2013) Clin Chem Lab Med 51, 1897-909.[IF=3.01] [SIGAPS=18] - Delaby C. & Lehmann (2013) Clin Chem Lab Med 52:649-55 [IF=3.01] [SIGAPS=18] - Un brevet intitulé « Method For In Vitro Diagnosis Of A Neurological Disorder » a été déposé le 15 mai 2013 à l'Office Européen des Brevets sous le n° EP13305614.3, Brevet français du CHRU de Montpellier/Université Montpellier 1. |
Manager
Sylvain LEHMANN
Details
tel: +33 (0)4 67 33 71 23 email: s-lehmann@chu-montpellier.fr Websites: http://www.chu-montpellier.fr/fr/coen/ http://www.chu-montpellier.fr/fr/chercheurs/plateformes/les-plateformes-recherche/collections-biologiques/ Group
LEHMANN Sylvain (PU-PH UM/CHU) DELABY Constance (MCU/UM) HIRTZ Christophe (MCU/UM) BROS Pauline (Doctorante/UM) VIALARET Jérome (IE/contractuel) TIERS Laurent (IE/CHU) MALESKA Aleksandra (IE/CHU) MOULINIER Amandine (Tech/CHU) GIRARD Marine (TRC/CHU) Keywords
Neurodegenerative diseases Biomarkers Clinical Biology Proteomics Technical skills
Biochemistry/proteomic:
|
